Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

 has approved bulevirtide (Hepcludex) injection for chronic 

 in adults without cirrhosis or with compensated cirrhosis.¹ Bulevirtide is the first FDA-approved therapy for chronic HDV infection. The agency granted approval of the first-in-class entry inhibitor to Gilead Sciences on May 22, 2026, under the Accelerated Approval pathway.¹

Until this decision, no antiviral was approved in the US specifically for HDV, and clinicians relied on off-label, interferon-based regimens with limited efficacy.

"Today's approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA-approved therapies available," said Wendy Carter, DO, acting director of the Office of Infectious Diseases in FDA’s Center for Drug Evaluation and Research. "For individuals living with this chronic viral infection, this new treatment option offers hope in managing a disease that can rapidly progress to serious liver complications."

MYR301, Buleviritde, and Hepatitis D Efficacy

The approval was supported by MYR301, a multicenter, randomized, open-label, parallel-arm phase 3 trial. Participants were assigned to immediate treatment with bulevirtide 8.5 mg once daily for 144 weeks or to delayed treatment, consisting of a 48-week observational period followed by bulevirtide 8.5 mg once daily for 96 weeks.¹

The primary efficacy endpoint was combined response at week 48. Combined response was defined as undetectable HDV RNA, reported as below the lower limit of quantification (LLOQ) of 50 IU/mL with target not detected, or a decline of at least 2 log10 IU/mL from baseline, together with alanine aminotransferase (ALT) normalization.¹

At week 48, combined response was achieved in 48% of patients in the bulevirtide group compared with 2% in the delayed-treatment group.¹ The 46-percentage-point difference formed the basis for the accelerated approval, with combined response serving as the primary efficacy endpoint. In MYR301, virologic suppression continued to deepen through 144 weeks, supporting extended dosing in responding patients.¹

Bulevirtide safety profile and boxed warning

Among secondary measures, the rate of undetectable HDV RNA at week 48 was 20% in the bulevirtide group compared with 0% in the delayed-treatment group.¹ Virologic suppression deepened with continued dosing. The proportion of patients with undetectable HDV RNA rose to 36% at week 96 and to 50% at week 144, indicating progressive response across the 144-week treatment period.¹

The most common adverse reactions reported with the once-daily injection include headache, abdominal pain, fatigue, and pruritus, along with injection site reactions.¹ Hypersensitivity reactions, including anaphylaxis, have also been reported.

The label carries a boxed warning for severe acute exacerbations of hepatitis. Discontinuation of bulevirtide may result in severe acute exacerbations of HDV and HBV infection, according to the FDA.¹ The warning is clinically relevant given the agent's chronic, multiyear dosing schedule.

The FDA granted bulevirtide Breakthrough Therapy and Orphan Drug designations, and the application received priority review.¹ The agency described the decision as part of its effort to expedite access to therapies for diseases with limited or no treatment options.¹

Bulevirtide already holds full marketing authorization in the European Union, the United Kingdom, and Switzerland for chronic HDV.

US Food and Drug Administration. FDA approves first treatment for chronic hepatitis delta virus (HDV) infection. Published May 22, 2026. Accessed May 22, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-hepatitis-…

Wedemeyer H, Aleman S, Brunetto MR, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. 

. 2023;389(1):22-32. doi:10.1056/NEJMoa2213429

Articles

The FDA granted accelerated approval to bulevirtide, a first-in-class entry inhibitor, for adults with chronic HDV infection without cirrhosis or with compensated cirrhosis, marking the first US-approved HDV therapy. Approval was supported by the phase 3 MYR301 trial using a week-48 combined endpoint of HDV RNA reduction/undetectability plus ALT normalization, achieved in 48% versus 2% with delayed treatment. Virologic responses deepened through 144 weeks. Key safety considerations include common injection-related AEs, rare hypersensitivity, and a boxed warning for severe hepatitis exacerbations after discontinuation.

Until this decision, clinicians relied on off-label, interferon-based regimens with limited efficacy.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

FDA News

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hepatology

Bulevirtide Receives Historic First FDA Approval for Chronic Hepatitis Delta

Ashkan Shoamanesh, MD, is an associate professor of medicine and the Marta and Owen Boris Chair in Stroke Research and Care at McMaster University.

Secondary Analyses of OCEANIC-STROKE Confirm Efficacy of Asundexian

Asundexian reduces stroke incidence and requires fewer interventions in patients after a non-cardioembolic 

 or high-risk transient ischemic attack (TIA), according to 4 late-breaking analyses presented at the European Stroke Organisation Conference (ESOC) 2026.

The original OCEANIC-STROKE study confirmed the efficacy of asundexian, an investigational oral Factor XIa (FXIa) inhibitor, for the prevention of ischemic stroke in patients following non-cardioembolic ischemic stroke or high-risk TIA. Despite having an overall minor role in the formation of hemostatic plugs to seal leaks at vessel injury sites, FXIa is believed to also contribute to the formation of pathological thrombus growth and vessel blockage as well.

“We’ve never had a trial previously where we’ve had such a large number of major and minor bleeds, and to see no excess risk with an antithrombotic versus placebo,” Ashkan Shoamanesh, MD, associate professor of medicine and Marta and Owen Boris Chair in Stroke Research and Care at McMaster University and co-principal investigator of the OCEANIC-STROKE trial, told 

 in an exclusive interview. “This would be the first time in history that we’ve seen this, and it really does make me hopeful about not only bringing this drug to market to implement the results we’ve seen thus far, but also what it could mean for cardiovascular disease on a broader scale.”

OCEANIC-STROKE was a phase 3, double-blind, event-driven, randomized, placebo-controlled trial conducted at 702 centers in 37 countries. Patients were eligible for inclusion if they had a non-cardioembolic ischemic stroke or high-risk TIA within 72 hours after the onset of symptoms. Those with ischemic stroke had a maximum score of 15 on the National Institutes of Health Stroke Scale (NIHSS), and high-risk TIA was defined as an ABCD2 score of 6 or 7. Patients who had undergone intravenous thrombolysis or mechanical thrombectomy were eligible if ≥24 hours had passed since treatment.

Eligible patients were randomly assigned in a 1:1 ratio to either asundexian 50 mg daily or matching placebo on top of planned dual or single antiplatelet therapy. The primary outcome was first occurrence of ischemic stroke, while secondary endpoints included any stroke, a composite of death from myocardial infarction, cardiovascular causes, or stroke, death from any cause, and TIA, among others.

A total of 12,327 patients were randomized, with 6162 receiving asundexian and 6165 receiving placebo. By the median follow-up of 567 days, a total of 1624 patients had discontinued asundexian and 1589 had discontinued placebo. Of the remainder, ischemic stroke occurred in 384 patients in the asundexian arm compared to 518 in the placebo arm (HR, 0.74; 95% CI, 0.65 to 0.84; 

In the present analyses of OCEANIC-STROKE, investigators examined several factors including the proportion of patients with a NIHSS score ≥8, the number of disabling strokes in each arm, the level of stroke severity in each arm, and the need for acute intervention in each arm. The results presented at ESOC 2026 largely supported the existing data of asundexian, reinforcing its efficacy for this population.

Key findings from these analyses included the following data:

Acute intervention: Of the ischemic strokes that did occur, 40 patients required acute intervention via intravenous thrombolysis and/or endovascular treatment in the asundexian group compared to 82 in the placebo group

Disabling/fatal stroke risk: Disabling stroke occurred in 2.1% of the asundexian group and 3%% in the placebo group (HR, 0.69; 96^ CI, 0.55-0.87)

Stroke severity: Moderate-to-high severity strokes (NIHSS ≥8) occurred in 88 patients in the asundexian group versus 157 in the placebo group

Ischemic stroke with fatal outcomes: 16 patients experienced fatal outcomes in the asundexian group versus 28 in the placebo group (HR, 0.57; 95% CI, 0.31-1.06)

With these data established and presented, Shoamanesh believes that the next step in the investigational and approval process for asundexian is confirmation of safety data.

“There’s no reason to believe that there’ll be any loss of safety over time,” Shoamanesh said. “If anything, we typically see with antithrombotics that the bleeding is front-loaded, and the further you go away from the time of initiation, the less the bleeding – that’s what the curves would suggest thus far, and that’s what we’ve seen in OCEANIC-STROKE.”

Editors’ Note: Shoamanesh reports disclosures with the Heart and Stroke Foundation of Canada, the Marta and Owen Boris Foundation, Bayer AG, Daiichi Sankyo, AstraZeneca, Octapharma, Inc., and others.

Bayer. Bayer announces new late-breaking data from OCEANIC-STROKE trial of asundexian. May 6, 2026. Accessed May 22, 2026. 

https://www.bayer.com/en/us/news-stories/data-from-oceanic-stroke-trial-of-asundexian

Sharma M, Dong Q, Hirano T, et al. Asundexian for secondary stroke prevention. 

Videos

Ashkan Shoamanesh, MD, discusses a series of abstracts presented at ESOC 2026 reinforcing asundexian’s protective effect in patients at risk of ischemic stroke or TIA.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Kilian Eyerich, MD, PhD, is chair and professor at the Department of Dermatology and Venerology of the University of Freiburg, Germany, as well as a guest professor at the Karolinska Institute in Stockholm, Sweden.

Kilian Eyerich, MD, PhD | Image credit: International Psoriasis Council

 evaluating lebrikizumab in adults with nummular eczema has been initiated by Almirall, broadening investigation of the interleukin (IL)-13 inhibitor beyond its currently approved use in moderate-to-severe atopic dermatitis. The analysis reflects the company’s continued focus on advancing targeted dermatology therapies while also incorporating patient-centered outcome measures into clinical research.

, Kilian Eyerich, MD, PhD, Eyerich described nummular eczema as a common yet historically understudied inflammatory skin condition. The disease lacks approved targeted medications, Eyerich noted, despite its significant impact on patients’ quality of life. Nummular eczema, also known as discoid eczema, is linked with chronic pruritus, recurrent flares, disruption of sleep, and psychosocial burden, and it can occur either independently or alongside atopic dermatitis.

Eyerich speaks in the second segment of his interview about several topics, including growing challenges faced by clinicians such as patient topical corticosteroid (TCS) hesitancy, withdrawal concerns, and the need for more effective treatment options for this difficult-to-control disease:

Many clinicians still rely heavily on topical corticosteroids for nummular eczema management. What challenges do you commonly see with current treatment approaches, particularly in patients with persistent or difficult-to-control disease?

 I think it's super important that you mention this exception. I would say in the majority of patients that have a mild no eczema, topical cortical steroids are still okay as long as we don't use them regularly and at high potency in sensitive areas. The main problem with TCS these days is that in the moderate and severe patients, they won't be enough. But that's only one point. Other aspects are that many patients just don't want it anymore, especially in the case of nummular eczema. These are often elderly patients that have treated their skin for many years, and they say, 'Please, every dermatologist tells me the same: use topical corticosteroids, I used them for a couple of days. Things get a little better, but as soon as I stop, the disease comes back worse than it was before.’

That's one aspect. Then we have a lot of topical corticosteroid phobia and topical corticosteroid withdrawal syndrome in social media, so it is pretty difficult to find an agreement on shared decision-making with the patients that should be on a topical corticosteroid scheme only. Again, if they have moderate to severe variants of nummular eczema, this is typically not enough. And we do see side effects of these TCS, especially in elderly patients that already have a thin skin. They tend to have an easy bleeding, wound healing, delay, and all the side effects that TCS have. In other words, modern and specific effective treatments and nummular eczema are desperately missing at this step, especially in a population with moderate to severe variants.

The LumiNE trial includes endpoints assessing investigator global assessment, itch reduction, and quality of life. Why is it important to evaluate both clinical severity and patient-reported burden in nummular eczema studies?

 This is a general insight that we in dermatology have made over the last decade or so, that in order to make a good shared decision process and treatment regimen, we always need the two different aspects. We need the physician-based, more or less objective, score, as well as patient-reported outcome measurements and insights, and in all kinds of dermatological diseases. But even beyond dermatology, typically, treatment aims and treatment goals nowadays consist of these two different aspects. It is a modern approach to look at the outcome of IL-13 inhibition and nominal eczema, and I think it is a very important one.

 As interest grows in targeted therapies across inflammatory skin diseases, how do you see studies like LumiNE shaping the future conversation around biologic treatment strategies beyond traditional atopic dermatitis indications?

Thank you very much for this question, because it's for sure a hard one, but it's a very interesting one. What I do see, and that's my honest opinion as a dermatologist, is that we and the whole discipline learn a lot from specifically acting agents, such as biologics and antibodies, because we again come from an era where only the phenotype matters to make up the diagnosis. In reality, phenotypes are overlapping and heterogeneous, and that's most likely why we do have a substantial proportion of non-responders in all kinds of clinical trials we do in dermatology.

Now, what we have to say is that using anti IL-13 as an example here, lebrikizumab, gives us also insights into the biology underlying the diseases. As I said before, nummular eczema has an IL-13 component, but also neutrophil granulocyte component. But we do see that IL-13 component seems to be the dominant one, and by shaping these individual diseases we get a better understanding of inflammatory skin diseases in general, where we do have atopic dermatitis and its sister disease, prurigo, but also now, nummular eczema. The next step for me would then be to identify that these diseases are somehow interrelated when it comes to therapeutic choice, right?

Neutralizing IL-13 would have a very high probability of success. The step after that, that's the future of dermatology in the field of inflammatory skin diseases. As I see it, it would be that we don't necessarily crawl on the traditional disease ontology, but rather we say, this is a group of diseases responding to, for example, interleukin-13 antagonists. Using that, we may get rid of the 99% of diagnoses at the moment that will always be off-label, because they are ill-defined, we don't have good endpoints there, they may be rare, but these patients should benefit actually from the development progress that we do, and not only the patients in the few diseases where we have studies investigating specific drugs.

The quotes contained in this video summary were edited for the purposes of clarity.

Disclosures: Eyerich has previously reported personal fees from Janssen, AbbVie, Almirall, Boehringer Ingelheim, LEO Pharma, Lilly, Novartis, and Sanofi.

Almirall announces “LumiNE”, a phase III clinical study assessing the efficacy of Lebrikizumab for the treatment of nummular eczema. Almirall, S.A. January 15, 2026. Accessed May 22, 2026. 

https://www.almirall.com/news-media/newsroom/almirall-announces-lumine-phase-iii-clinical-study-assessing-efficacy

Böhner A, Jargosch M, Eyerich K, et al. The neglected twin: Nummular eczema is a variant of atopic dermatitis with codominant TH2/TH17 immune response. J Allergy Clin Immunol. 2023 Aug;152(2):408-419. doi: 10.1016/j.jaci.2023.04.009. Epub 2023 Apr 27. PMID: 37119871.

Phase 3 LumiNE trial is testing lebrikizumab, an IL-13 inhibitor, in adults with nummular eczema, extending development beyond moderate-to-severe atopic dermatitis. The condition is common yet understudied, lacks approved targeted options, and causes chronic pruritus, recurrent flares, sleep disruption, and psychosocial burden, often in older patients. Topical corticosteroids may help mild disease but are often inadequate for moderate-to-severe cases and complicated by steroid hesitancy, withdrawal narratives, and cutaneous adverse effects. Endpoints combining investigator assessment with itch and quality-of-life measures support shared decision-making and endotype-driven biologic strategies.

This segment of a Q&A interview with Kilian Eyerich, MD, PhD, highlights the signficance of the LumiNE phase 3 study on lebrikizumab.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Significance of New Phase 3 Lebrikizumab Trial in Nummular Eczema, With Kilian Eyerich, MD, PhD

Ann Marie Navar, MD, PhD, is an associate professor of cardiology at the University of Texas Southwestern Medical Center.

Advancing ASCVD Management with PCSK9 Inhibitors

In this episode, ‘Advancing ASCVD Management with PCSK9 Inhibitors,' the panelists explore the clinical evidence base for PCSK9 inhibitors, beginning with a review of outcomes trial data from FOURIER and ODYSSEY Outcomes showing 50 to 60% LDL reductions with evolocumab and alirocumab, and relative risk reductions of approximately 15% in secondary prevention, rising to 25% in the more recent VICTORION primary prevention trial. Both FOURIER and ODYSSEY Outcomes demonstrated reductions in total mortality, and safety data have consistently shown no concerning signals at very low LDL levels, including no adverse cognitive effects even at dramatically reduced LDL concentrations. The panel also highlights that PCSK9 inhibitors provide an additional 25% reduction in lipoprotein(a), with patients carrying higher baseline levels deriving greater absolute benefit, a finding now reflected in the 2026 guidelines recommending PCSK9 inhibitor consideration in high-risk secondary prevention patients with elevated lipoprotein(a).

The panelists also reference the VICTORION-INITIATE trial, which demonstrated that facilitating early initiation of inclisiran through a dedicated support team improved both adherence and overall cardiovascular risk factor management, reinforcing the value of structured implementation approaches over sequential therapy escalation.

The conversation then turns to enlicitide, an investigational oral PCSK9 inhibitor described as a macrocyclic peptide that binds to PCSK9 in serum and prevents LDL receptor degradation through the same biological mechanism as monoclonal antibodies. Data from the Coral Reef lipids trial show nearly identical LDL lowering with enlicitide compared to injectable monoclonal antibodies, with outcomes trial results from Coral Reef anticipated through 2029.

The next episode in this series, 'Safety, Tolerability, and Patient-Centered Decision-Making in ASCVD Lipid Therapy,' features the panelists advancing their conversation on ASCVD and focusing on the safety and tolerability profiles of statins, PCSK9 inhibitors, and emerging oral therapies, while examining how patient preferences, dosing frequency, and shared decision-making shape individualized treatment choices.

Explore where ezetimibe and bempedoic acid fit for statin‑reluctant patients, lowering LDL with proven outcomes and diabetes benefits.

The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction

This episode, titled 'The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction,' features expert cardiologists discussing the expanding role of non-statin oral therapies in lipid management, with a particular focus on ezetimibe and bempedoic acid as viable options for both statin-intolerant and statin-reluctant patients. The panel introduces the concept of statin reluctance to describe patients who firmly decline statin therapy regardless of clinical rationale, emphasizing that clinicians must respect patient preferences and work within those boundaries rather than risk losing the patient from care entirely. Ezetimibe is highlighted as a highly versatile agent, effective as monotherapy and as an add-on to statins, with one panelist referencing the well-established principle that doubling a statin dose yields only an additional 6% LDL reduction, making the addition of ezetimibe a far more efficient strategy for further lowering. The panel also notes that individual variability in cholesterol absorption means ezetimibe's efficacy can differ substantially between patients, reinforcing the value of a trial-based approach.

The discussion further explores bempedoic acid as a statin alternative with a favorable tolerability profile and notes its additional benefit of counteracting the diabetogenic effect associated with statin use, making it a particularly attractive option in patients at risk for diabetes. The panelists reinforce that both agents are supported by clinical outcomes trial data demonstrating reductions in cardiovascular events and emphasize that LDL lowering through any validated mechanism translates into meaningful clinical benefit. The episode closes by underscoring that there are now five distinct evidence-based pathways to reduce LDL cholesterol and cardiovascular events, offering clinicians an increasingly flexible toolkit to personalize ASCVD management across a wide range of patient profiles.

In the next episode, ‘Advancing ASCVD Management with PCSK9 Inhibitors,' panelists will continue their discussion on ASCVD and highlight the robust clinical outcomes data supporting PCSK9 inhibitor use in high and very high-risk patients, while examining how emerging oral PCSK9 inhibitors and innovative trial designs are poised to further transform the lipid-lowering treatment landscape.

Geoffrey Tison, MD, MPH, is the co-director of the University of California San Francisco Center for Biosignal Research.

Joshua Barrios, PhD, and Geoffrey Tison, MD, MSc, discuss their new AI echo’s comparative superiority in identifying cardiovascular disease.

New AI Model Outperforms Standard Echocardiograms in Heart Disease Detection

A new phase 3 study is evaluating lebrikizumab in at least 270 patients with nummular eczema over 48 weeks.


Phase 3 LumiNE Trial to Assess Lebrikizumab in Nummular Eczema, With Kilian Eyerich, MD, PhD

Jane Wilcox, MD, MSc, is the section chief of heart failure treatment and recovery at Northwestern Feinberg School of Medicine.

Wilcox discusses the recent HFSA statement aiming to identify the unique characteristics of HFmrEF and define an alternative treatment pathway.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

HFmrEF as a Unique Phenotype of Heart Failure, With Jane Wilcox, MD, MSc

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The FDA accepted Bayer’s sNDA for finerenone in adults with type 1 diabetes and CKD based on albuminuria data from FINE-ONE.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

FDA Grants Priority Review to Finerenone for Type 1 Diabetes and CKD

Retatrutide successfully reduced body weight versus placebo in adults with obesity or overweight in topline phase 3 TRIUMPH-1 results.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Retatrutide Meets Weight Loss Endpoints in Phase 3 Obesity Trial

Klaus F. Rabe, MD, PhD, from LungenClinic Grosshansdorf GmbH. 

Klaus Friedrich Rabe, MD, PhD, spoke at ATS about the mixed phase 3 AERIFY trial findings on itepekimab, an anti–IL-33 monoclonal antibody, in COPD.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD

New ATP7B gene therapies aim to normalize copper in Wilson’s disease, reducing chelation needs while raising durability and patient-selection questions.

Video Series

Real-World Evidence and Strategies for Long-Term Adherence in Wilson Disease

Gene Therapy as an Emerging Treatment Approach in Wilson Disease

In the final episode, each panelist synthesizes their top recommendations for advancing EPI care.

Closing the Loop: Key Recommendations and Future Directions for EPI

At ATS, Klaus Friedrich Rabe, MD, PhD, discussed phase 3 data on itepekimab in former smokers with chronic obstructive pulmonary disease (COPD).

Latest News

Bulevirtide Receives Historic First FDA Approval for Chronic Hepatitis Delta

Secondary Analyses of OCEANIC-STROKE Confirm Efficacy of Asundexian

Significance of New Phase 3 Lebrikizumab Trial in Nummular Eczema, With Kilian Eyerich, MD, PhD

Advancing ASCVD Management with PCSK9 Inhibitors

The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction